The economic burden of dry eye: A conceptual framework and preliminary assessment

Cornea

Volumn 23, Issue 8, 2004, Pages 751-761

  Reddy, Prabashni ^a   Grad, Oren ^a   Rajagopalan, Krithika ^b,c  

^a ABT ASSOCIATES   (United States)

^b ALCON RESEARCH LTD   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Cost of illness; Dry eye; Economics

Indexed keywords

AMIODARONE; ANDROGEN; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; ARTIFICIAL TEAR; BOTULINUM TOXIN; CALCIUM; CEVIMELINE; CORTICOSTEROID; CYCLOSPORIN; ELEDOISIN; ESTROGEN; FISH OIL; INTERFERON; ISOTRETINOIN; LINSEED OIL; N,N DIMETHYLPHENETHYLAMINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; PURINERGIC RECEPTOR STIMULATING AGENT; RETINOL; TACROLIMUS; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ARTICLE; BLEPHARITIS; CATARACT; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG COST; DRUG INDICATION; DRY EYE; ECONOMIC ASPECT; ECONOMIC EVALUATION; EYE SURGERY; GLAUCOMA; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; KERATOMILEUSIS; MEDICAL FEE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SUPERINFECTION; TREATMENT INDICATION;

COST OF ILLNESS; DATABASES, FACTUAL; DRUG COSTS; DRY EYE SYNDROMES; HEALTH RESOURCES; HUMANS; OPHTHALMIC SOLUTIONS; OPHTHALMOLOGIC SURGICAL PROCEDURES; OPHTHALMOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 7444240267     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000134183.47687.75     Document Type: Article

References (84)

1. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221-232.
2. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol. 2001;45(Suppl 2):S199-S202.
3. Bjerrum KB. Keratoconjunctivitis sicca and primary Sjogren's syndrome in a Danish population aged 30-60 years. Acta Ophthalmol Scand. 1997; 75:281-286.
4. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159:1359-1363.
5. Bandeen-Roche K, Munoz B, Tielsch JM, et al. Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci. 1997;38:2469-2475.
6. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723-728.
7. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268.
8. Albietz JM. Prevalence of dry eye subtypes in clinical optometry practice. Optom Vis Sci. 2000;77:357-363.
9. Caffery BE, Richter D, Simpson T, et al. CANDEES. The Canadian Dry Eye Epidemiology Study. Adv Exp Med Biol. 1998;438:805-806.
10. Doughty MJ, Fonn D, Richter D, et al. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci. 1997;74:624-631.
11. Hikichi T, Yoshida A, Fukui Y, et al. Prevalence of dry eye in Japanese eye centers. Graefes Arch Clin Exp Ophthalmol. 1995;233:555-558.
12. Goto E, Yagi Y, Matsumoto Y, et al. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol. 2002;133:181-186.
13. Rolando M, Iester M, Macri A, et al. Low spatial-contrast sensitivity in dry eyes. Cornea. 1998;17:376-379.
14. Liu Z, Pflugfelder SC. Corneal thickness is reduced in dry eye. Cornea. 1999;18:403-407.
15. Nelson JD, Helms H, Fiscella R, et al. A new look at dry eye disease and its treatment. Adv Ther. 2000;17:84-93.
16. Sanchez LA. Pharmacoeconomics: Principles. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. Stamford: Appleton & Lange, 1998:1-11.
17. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma. 2001;10:184-191.
18. Calonge M. The treatment of dry eye. Surv Ophthalmol. 2001;45(Suppl 2):S227-S239.
19. National Physician Fee Schedule and Relative Value Fees. Centers for Medicare and Medicaid Services. March 18, 2003. Available at www.cms.gov/physicians. Accessed June 2, 2003.
20. RedBook™ Windows (computer program). Greenwood Village, CO: Micromedex, 2003.
21. Online Pharmacy CVS. June 2, 2003. Available at www.cvs.com. Accessed June 2, 2003.
22. VisionWorks. May 12, 2003. Available at www.visionworksusa.com. Accessed May 12, 2003.
23. Nutritional Research. Dry eye products. Available at www. nutritionalresearch.net/productsdryeyes.htm5. Accessed May 12, 2003.
24. Oliveira-Soto L, Charman WN. Some possible longer-term ocular changes following excimer laser refractive surgery. Ophthalmic Physiol Opt. 2002;22:274-288.
25. Albietz JM, Lenton LM, McLennan SG. Effect of laser in situ keratomileusis for hyperopia on tear film and ocular surface. J Refract Surg. 2002; 18:113-123.
26. Ang RT, Dartt DA, Tsubota K. Dry eye after refractive surgery. Curr Opin Ophthalmol. 2001;12:318-322.
27. Toda I, Asano-Kato N, Hori-Komai Y, et al. Laser-assisted in situ keratomileusis for patients with dry eye. Arch Ophthalmol. 2002;120:1024-1028.
28. Toda I, Yagi Y, Hata S, et al. Excimer laser photorefractive keratectomy for patients with contact lens intolerance caused by dry eye. Br J Ophthalmol. 1996;80:604-609.
29. Ikaheimo K, Kettunen R, Mantyjarvi M. Visual functions and adverse ocular effects in patients with amiodarone medication. Acta Ophthalmol Scand. 2002;80:59-63.
30. Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114-2119.
31. Bozkurt B, Irkec MT, Atakan N, et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol. 2002;12:173-176.
32. Cotler SJ, Wartelle CF, Larson AM, et al. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat. 2000;7:211-217.
33. Eter N, Schuller H. External beam radiotherapy for age-related macular degeneration causes transient objective changes in tear-film function. Graefes Arch Clin Exp Ophthalmol. 2001;239:923-926.
34. Parsons JT, Bova FJ, Mendenhall WM, et al. Response of the normal eye to high dose radiotherapy. Oncology (Huntingt). 1996;10:837-847.
35. Koshy S, Daniel E, Kurian N, et al. Pathogenesis of dry eye in leprosy and tear functions. Int J Lepr Other Mycobact Dis. 2001;69:215-218.
36. Cordido M, Fernandez-Lago C, Fernandez-Vigo J, et al. Dry eye in Waldenstrom's macroglobulinemia. Improvement after systemic chemotherapy. Cornea. 1995;14:210-211.
37. Mathers WD, Stovall D, Lane JA, et al. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea. 1998;17:353-358.
38. American Academy of Ophthalmology. Dry Eye Syndrome. Washington, DC: AAO, 1998.
39. Shimmura S, Shimazaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea. 1999;18:408-411.
40. Nichols KK, Begley CG, Caffery B, et al. Symptoms of ocular irritation in patients diagnosed with dry eye. Optom Vis Sci. 1999;76:838-844.
41. Begley CG, Chalmers RL, Mitchell GL, et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea. 2001;20:610-618.
42. Begley CG, Caffery B, Chalmers RL, et al. Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea. 2002;21:664-670.
43. Begley CG, Caffery B, Nichols KK, et al. Responses of contact lens wearers to a dry eye survey. Optom Vis Sci. 2000;77:40-46.
44. Lemp MA. Evaluation and differential diagnosis of keratoconjunctivitis sicca. J Rheumatol Suppl. 2000;61:11-14.
45. Kallarackal GU, Ansari EA, Amos N, et al. A comparative study to assess the clinical use of Fluorescein Meniscus Time (FMT) with Tear Break up Time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes. Eye. 2002;16:594-600.
46. Versura P, Cellini M, Torreggiani A, et al. Dryness symptoms, diagnostic protocol and therapeutic management: a report on 1,200 patients. Ophthalmic Res. 2001;33:221-227.
47. Patel S, Farrell J, Blades KJ, et al. The value of a phenol red impregnated thread for differentiating between the aqueous and non-aqueous deficient dry eye. Ophthalmic Physiol Opt. 1998;18:471-476.
48. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000;19:644-649.
49. Korb DR. Survey of preferred tests for diagnosis of the tear film and dry eye. Cornea. 2000;19:483-486.
50. Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea. 2000; 19:477-482.
51. Eter N, Gobbels M. A new technique for tear film fluorophotometry. Br J Ophthalmol. 2002;86:616-619.
52. Abetz L, Venkataraman K, Mertzanis P, et al. Assessing the impact of dry eyes on everyday life. Optom Vis Sci. 2002;79:304.
53. Restasis Product Information. Irvine, CA: Allergan Inc, 2002.
54. Biswas NR, Gupta SK, Das GK, et al. Evaluation of Ophthacare eye drops-a herbal formulation in the management of various ophthalmic disorders. Phytother Res. 2001;15:618-620.
55. Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea. 2001;20:430-434.
56. Vivino FB, Al Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159:174-181.
57. Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea. 2000;19:145-147.
58. Petricek I, Pokupec R, Petricek G, et al. Lodoxamide as adjuvant therapy in patients with dry eye. Coll Antropol. 2001;25(Suppl):149-152.
59. Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802-806.
60. Schoenwald RD, Vidvauns S, Wurster DE, et al. Tear film stability of protein extracts from dry eye patients administered a sigma agonist. J Ocul Pharmacol Ther. 1997;13:151-161.
61. Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr. 2001;55:589-597.
62. Tsubota K, Monden Y, Yagi Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol. 1999; 83:767-770.
63. Steinfeld SD, Demols P, Van Vooren JP, et al. Zidovudine in primary Sjogren's syndrome. Rheumatology (Oxford). 1999;38:814-817.
64. Gilbard JP. Dry eye, blepharitis and chronic eye irritation: divide and conquer. J Ophthalmic Nurs Technol. 1999;18:109-115.
65. Murube J, Murube E. Treatment of dry eye by blocking the lacrimal canaliculi. Surv Ophthalmol. 1996;40:463-480.
66. American Academy of Ophthalmology. Punctal occlusion for the dry eye. Three-year revision. Ophthalmology. 1997;104:1521-1524.
67. Hutnik CM, Probst LE. Argon laser punctal therapy versus thermal cautery for the treatment of aqueous deficiency dry eye syndrome. Can J Ophthalmol. 1998;33:365-372.
68. Rumelt S, Remulla H, Rubin PA. Silicone punctal plug migration resulting in dacryocystitis and canaliculitis. Cornea. 1997;16:377-379.
69. Hsu HC. Ampullary pyogenic granuloma as a complication of lacrimal plug migration. Chang Gung Med J. 2002;25:415-418.
70. Tai MC, Cosar CB, Cohen EJ, et al. The clinical efficacy of silicone punctal plug therapy. Cornea. 2002;21:135-139.
71. Cosar CB, Cohen EJ, Rapuano CJ, et al. Tarsorrhaphy: clinical experience from a cornea practice. Cornea. 2001;20:787-791.
72. Lauer I, Sieg P, Bahre M, et al. Salivary gland scintigraphy using technetium-99m-pertechnetate after autotransplantation of the submandibular salivary gland in the correction of dry eye. Eur J Nucl Med. 1998;25:128-131.
73. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86:181-184.
74. Sieg P, Geerling G, Kosmehl H, et al. Microvascular submandibular gland transfer for severe cases of keratoconjunctivitis sicca. Plast Reconstr Surg. 2000;106:554-560.
75. Geerling G, Sieg P, Bastian GO, et al. Transplantation of the autologous submandibular gland for most severe cases of keratoconjunctivitis sicca. Ophthalmology. 1998;105:327-335.
76. Swanson M. Compliance with and typical usage of artificial tears in dry eye conditions. J Am Optom Assoc. 1998;69:649-655.
77. Cross WD, Lay LF Jr, Walt JG, et al. Clinical and economic implications of topical cyclosporin A for the treatment of dry eye. Manag Care Interface. 2002;15:44-49.
78. Small minority accounts for majority of botanical product sales: American Botanical Council. Available at www.herbalgram.org/herbalgram/ articleview.asp?a2370. Accessed May 27, 2003.
79. Yazdani C, McLaughlin T, Smeeding JE, et al. Prevalence of treated dry eye disease in a managed care population. Clin Ther. 2001;23:1672-1682.
80. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol. 2001;131:30-36.
81. Guzey M, Ozardali I, Kilic A, et al. The treatment of severe trachomatous dry eye with canalicular silicone plugs. Eye. 2001;15:297-303.
82. Yokoi N, Okada K, Sugita J, et al. Acute conjunctivitis associated with biofilm formation on a punctal plug. Jpn J Ophthalmol. 2000;44:559-560.
83. Farhadi A, Bruninga K, Fields J, et al. Irritable bowel syndrome: an update on therapeutic modalaties. Expert Opin Investig Drugs. 2003;10:1211-1222.
84. National Center for Complementary and Alternative Medicine. May 30, 2003. Available at www.nccam.nih.gov. Accessed June 2, 2003.